Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Lianes

Showing results (11-20 of 48) with videos related to

Pageof 5
Sort By:
Cancer Treatment Reviews|July 9, 2013
Acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in EGFR-mutant non-small cell lung cancer: a new era beginsJ Remon, T Morán, M Majem, et al.
The Journal of Urology|May 7, 2002
Primary cisplatin, methotrexate and vinblastine chemotherapy with selective bladder preservation for muscle invasive carcinoma of the bladder: long-term followup of a prospective studyF de la Rosa, R Garcia-Carbonero, J Passas, et al.
Revista Clinica Espanola|July 1, 1997
[Long-term course of blood lipids and body mass index in patients with testicular cancer treated with chemotherapy]C Fernández-Miranda, N Schoebel, A Angulo, et al.
Journal of the National Cancer Institute|September 7, 1994
Altered patterns of MDM2 and TP53 expression in human bladder cancerP Lianes, I Orlow, Z F Zhang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 1, 1995
Phase I/II trial of dexverapamil plus vinblastine for patients with advanced renal cell carcinomaR J Motzer, P Lyn, P Fischer, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 1, 1993
CMV front-line chemotherapy in transitional bladder carcinomaL Paz-Ares, P Lianes, M Díaz-Puente, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 13, 2005
Second-line (post-study) chemotherapy received by patients treated in the phase III trial of pemetrexed plus cisplatin versus cisplatin alone in malignant pleural mesotheliomaC Manegold, J Symanowski, U Gatzemeier, et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|August 2, 2019
Treatment options beyond immunotherapy in patients with wild-type lung adenocarcinoma: a Delphi consensusD Isla, J de Castro, R García-Campelo, et al.
The Cancer Journal From Scientific American|October 1, 1995
Final report of a phase II study of chemotherapy with bleomycin, epirubicin, and cisplatin for locally advanced and metastatic/recurrent undifferentiated carcinoma of the nasopharyngeal typeN Azli, A Fandi, M Bachouchi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 1, 1995
Changing pattern of expression of the epidermal growth factor receptor and transforming growth factor alpha in the progression of prostatic neoplasmsH I Scher, A Sarkis, V Reuter, et al.
Pageof 5

Showing results (11-20 of 48) with videos related to

Sort By:
Pageof 5
Cancer Treatment Reviews|July 9, 2013
Acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in EGFR-mutant non-small cell lung cancer: a new era beginsJ Remon, T Morán, M Majem, et al.
The Journal of Urology|May 7, 2002
Primary cisplatin, methotrexate and vinblastine chemotherapy with selective bladder preservation for muscle invasive carcinoma of the bladder: long-term followup of a prospective studyF de la Rosa, R Garcia-Carbonero, J Passas, et al.
Revista Clinica Espanola|July 1, 1997
[Long-term course of blood lipids and body mass index in patients with testicular cancer treated with chemotherapy]C Fernández-Miranda, N Schoebel, A Angulo, et al.
Journal of the National Cancer Institute|September 7, 1994
Altered patterns of MDM2 and TP53 expression in human bladder cancerP Lianes, I Orlow, Z F Zhang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 1, 1995
Phase I/II trial of dexverapamil plus vinblastine for patients with advanced renal cell carcinomaR J Motzer, P Lyn, P Fischer, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 1, 1993
CMV front-line chemotherapy in transitional bladder carcinomaL Paz-Ares, P Lianes, M Díaz-Puente, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 13, 2005
Second-line (post-study) chemotherapy received by patients treated in the phase III trial of pemetrexed plus cisplatin versus cisplatin alone in malignant pleural mesotheliomaC Manegold, J Symanowski, U Gatzemeier, et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|August 2, 2019
Treatment options beyond immunotherapy in patients with wild-type lung adenocarcinoma: a Delphi consensusD Isla, J de Castro, R García-Campelo, et al.
The Cancer Journal From Scientific American|October 1, 1995
Final report of a phase II study of chemotherapy with bleomycin, epirubicin, and cisplatin for locally advanced and metastatic/recurrent undifferentiated carcinoma of the nasopharyngeal typeN Azli, A Fandi, M Bachouchi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 1, 1995
Changing pattern of expression of the epidermal growth factor receptor and transforming growth factor alpha in the progression of prostatic neoplasmsH I Scher, A Sarkis, V Reuter, et al.
Pageof 5